COVID-19 oral treatment eligibility expanded from 11 July 2022

From 11 July 2022, more Australians at higher risk of developing severe COVID-19 will be able to access oral antiviral treatments following new recommendations from the Pharmaceutical Benefits Advisory Committee.

Date published:
General public

More people at higher risk of severe illness from COVID-19 will be able to access life-saving oral antiviral treatments from Monday 11 July.

The prescription-only oral treatments, Paxlovid and Lagevrio, have been found to be effective in treating mild to moderate COVID-19 in adults aged 18 years of age and older, who do not require supplemental oxygen, and who are at increased risk of progressing to hospitalisation.

New eligibility includes updated age limits and risk factors.

Find out more about your risk factors and expanded eligibility.

Find out more about Paxlovid and Lagevrio.

PBAC Web Outcome Statement.

Help us improve

If you would like a response please use the enquiries form instead.